CA Patent

CA2513623A1 — Compositions and methods for sirna inhibition of icam-1

Assigned to University of Pennsylvania Penn · Expires 2004-08-05 · 22y expired

What this patent protects

RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from typ…

USPTO Abstract

RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.

Drugs covered by this patent

Patent Metadata

Patent number
CA2513623A1
Jurisdiction
CA
Classification
—
Expires
2004-08-05
Drug substance claim
No
Drug product claim
No
Assignee
University of Pennsylvania Penn
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.